Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice.
D-amino acid oxidase inhibitor
PK/PD, multilayer quantitative model
TAK-831
target occupancy
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
05 Aug 2020
05 Aug 2020
Historique:
received:
08
05
2020
accepted:
24
07
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
16
6
2021
Statut:
epublish
Résumé
TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concentrations as a pharmacodynamic (PD) readout was established in mice. PK, TO and PD time-profiles were obtained in mice and analyzed by mechanistic binding kinetics model connected with an indirect response model in a step wise fashion. Brain distribution was investigated to elucidate a possible mechanism driving the hysteresis between PK and TO. The observed nonlinear PK/TO/PD relationship was well captured by mechanistic modeling framework within a wide dose range of TAK-831 in mice. Remarkably different brain distribution was observed between target and reference regions, suggesting that the target-mediated slow binding kinetics rather than slow penetration through the blood brain barrier caused the observed distinct kinetics between PK and TO. A quantitative mechanistic model for concentration- and time-dependent nonlinear PK/TO/PD relationship was established for TAK-831 in mice with accounting for possible rate-determining process. The established mechanistic modeling framework will provide a quantitative means for multilayer biomarker-assisted clinical development in multiple central nervous system indications.
Identifiants
pubmed: 32901384
doi: 10.1007/s11095-020-02893-x
pii: 10.1007/s11095-020-02893-x
pmc: PMC7478952
doi:
Substances chimiques
D-Amino-Acid Oxidase
EC 1.4.3.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
164Références
Drug Metab Dispos. 2012 Nov;40(11):2067-73
pubmed: 22837388
J Chromatogr. 1992 Nov 6;582(1-2):41-8
pubmed: 1491056
Drug Discov Today. 2017 Oct;22(10):1447-1459
pubmed: 28476536
Brain Res. 1994 Aug 1;652(2):297-303
pubmed: 7953743
J Neurochem. 2011 Apr;117(2):333-45
pubmed: 21291474
J Pharm Sci. 2013 Sep;102(9):3343-55
pubmed: 23650139
Neurochem Res. 2017 Nov;42(11):3279-3288
pubmed: 28780732
Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15
pubmed: 21763704
J Chromatogr B Biomed Sci Appl. 2001 Jun 5;757(1):119-25
pubmed: 11419736
Front Mol Biosci. 2018 Jun 12;5:55
pubmed: 29946548
J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
pubmed: 17519979
Neurosci Lett. 2020 May 1;726:133664
pubmed: 29966749
AAPS J. 2015 Mar;17(2):462-73
pubmed: 25630504
Schizophr Res. 2010 Aug;121(1-3):125-30
pubmed: 20541910
J Cereb Blood Flow Metab. 2011 Mar;31(3):944-52
pubmed: 20940733
CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):777-791
pubmed: 31535440
Drug Metab Dispos. 2009 Jul;37(7):1548-56
pubmed: 19389861
Br J Clin Pharmacol. 2005 Jun;59(6):705-11
pubmed: 15948935
Br J Pharmacol. 2010 May;160(2):389-98
pubmed: 20423348
Br J Pharmacol. 2014 Mar;171(5):1241-9
pubmed: 24670146
J Pharm Sci. 2011 Sep;100(9):3939-50
pubmed: 21254069
Biochem Soc Trans. 2013 Dec;41(6):1551-6
pubmed: 24256253
CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):5-20
pubmed: 31674729
J Pharm Sci. 2018 Aug;107(8):2225-2235
pubmed: 29608887
J Cereb Blood Flow Metab. 2013 May;33(5):700-7
pubmed: 23385202
Nat Neurosci. 2011 May;14(5):603-11
pubmed: 21460832
PLoS One. 2011;6(5):e20472
pubmed: 21629771
Pharm Res. 2008 Aug;25(8):1737-50
pubmed: 18058202